Analysis of clinical value of low dose of Oxaliplatin combined with transcatheter arterial chemoembolization in the treatment of primary hepatic carcinoma in elderly patients
10.3760/cma.j.issn.0254-9026.2017.04.019
- VernacularTitle:低剂量奥沙利铂联合肝动脉化疗栓塞术治疗老年原发性肝癌患者的临床价值
- Author:
Yong WANG
;
Suping FENG
;
Guoxin HOU
- Keywords:
Liver neoplasms;
Antineoplastic combined chemotherapy protocols;
Embolization,therapeutic
- From:
Chinese Journal of Geriatrics
2017;36(4):433-435
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the adverse reactions and survival rate of low dose of Oxaliplatin combined with transcatheter arterial chemoembolization in treatment of elderly patients with primary hepatic carcinoma.Methods A total of 84 patients with primary liver cancer were enrolled and randomly divided into low dose group and high dose group.Patients received 40 mg/m2 and 80 mg/m2 of Oxaliplatin respectively,and adverse reactions and survival rate were compared between the two groups.Results Incidence of nausea and vomiting was obviously lower and the number of patients with pain scale above 6 was significantly smaller in low dose group than in high dose group,with statistically significant differences (11.9％ vs.21.4％ and 28.6％ vs.78.6％,x2 =9.910,20.056,both P ＜ 0.05).White blood cell count was significantly higher and alanine aminotransferase (ALT) was significantly lower in low dose group than in high dose group after treatment (t =13.447,6.774,both P＜0.05).1 year and 3 year survival rate was 69.05％ and 30.95％ in low dose group and 61.9％ and 21.43％ in high dose group,respectively,with no statistically significant difference (x2 =0.474 and 0.985,P=0.491 and 0.321).Conclusions Low dose of Oxaliplatin combined with transcatheter arterial chemoembolization in the treatment of elderly patients with primary hepatocellular carcinoma is worth to be promoted in clinical application because it does not affect the patient survival rate and the toxic effects of the chemotherapy are very little.
